title: Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study.
abstract: OBJECTIVE
  Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue.
  
  
  METHODS
  Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy.
  
  
  RESULTS
  New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P=.0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76).
  
  
  CONCLUSIONS
  The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy.
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España.
authors.forename: Enrique Javier
authors.initials: EJ
authors.lastname: Díaz Convalía
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España.
authors.forename: María Del Carmen
authors.initials: MDC
authors.lastname: Cano-García
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Miján-Ortiz
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España.
authors.forename: Miguel
authors.initials: M
authors.lastname: Arrabal-Martín
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España. Electronic address: arrabalp@ono.com.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Arrabal-Polo
authors.affiliation: Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Cózar-Olmo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007669:Kidney Calculi / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone
keywords: Androgen deprivation therapy; Análogos LHRH; Cáncer de próstata; LHRH analogues; Litiasis renal; Prostate cancer; Renal stones; Tratamiento de privación androgénica